vs

Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Turtle Beach Corp (TBCH). Click either name above to swap in a different company.

Turtle Beach Corp is the larger business by last-quarter revenue ($95.1M vs $70.9M, roughly 1.3× Adaptive Biotechnologies Corp). Turtle Beach Corp runs the higher net margin — 18.5% vs 4.7%, a 13.8% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs -34.9%). Over the past eight quarters, Turtle Beach Corp's revenue compounded faster (30.5% CAGR vs 28.1%).

ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.

The Turtle Beach Corporation is an American gaming accessory manufacturer based in San Diego, California. The company has roots dating back to the 1970s where it developed sound cards, MIDI synthesizers, and various audio software packages and network audio devices. The company began making gaming headsets in 2005.

ADPT vs TBCH — Head-to-Head

Bigger by revenue
TBCH
TBCH
1.3× larger
TBCH
$95.1M
$70.9M
ADPT
Growing faster (revenue YoY)
ADPT
ADPT
+70.0% gap
ADPT
35.1%
-34.9%
TBCH
Higher net margin
TBCH
TBCH
13.8% more per $
TBCH
18.5%
4.7%
ADPT
Faster 2-yr revenue CAGR
TBCH
TBCH
Annualised
TBCH
30.5%
28.1%
ADPT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ADPT
ADPT
TBCH
TBCH
Revenue
$70.9M
$95.1M
Net Profit
$3.4M
$17.6M
Gross Margin
73.6%
50.0%
Operating Margin
-27.1%
22.0%
Net Margin
4.7%
18.5%
Revenue YoY
35.1%
-34.9%
Net Profit YoY
-12.6%
EPS (diluted)
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADPT
ADPT
TBCH
TBCH
Q1 26
$70.9M
Q4 25
$71.7M
$95.1M
Q3 25
$94.0M
$80.5M
Q2 25
$58.9M
$80.5M
Q1 25
$52.4M
$63.9M
Q4 24
$47.5M
$146.1M
Q3 24
$46.4M
$94.4M
Q2 24
$43.2M
$76.5M
Net Profit
ADPT
ADPT
TBCH
TBCH
Q1 26
$3.4M
Q4 25
$-13.6M
$17.6M
Q3 25
$9.5M
$1.7M
Q2 25
$-25.6M
$-2.9M
Q1 25
$-29.9M
$-664.0K
Q4 24
$-33.7M
$20.1M
Q3 24
$-32.1M
$3.4M
Q2 24
$-46.2M
$-7.5M
Gross Margin
ADPT
ADPT
TBCH
TBCH
Q1 26
73.6%
Q4 25
74.6%
50.0%
Q3 25
80.7%
37.4%
Q2 25
69.4%
22.7%
Q1 25
67.6%
36.6%
Q4 24
62.0%
37.0%
Q3 24
64.1%
36.2%
Q2 24
55.3%
30.2%
Operating Margin
ADPT
ADPT
TBCH
TBCH
Q1 26
-27.1%
Q4 25
-17.8%
22.0%
Q3 25
10.9%
6.7%
Q2 25
-42.5%
-0.4%
Q1 25
-56.4%
2.4%
Q4 24
-71.3%
16.0%
Q3 24
-70.3%
6.8%
Q2 24
-109.6%
-5.4%
Net Margin
ADPT
ADPT
TBCH
TBCH
Q1 26
4.7%
Q4 25
-18.9%
18.5%
Q3 25
10.2%
2.1%
Q2 25
-43.5%
-3.6%
Q1 25
-56.9%
-1.0%
Q4 24
-71.0%
13.8%
Q3 24
-69.1%
3.6%
Q2 24
-107.0%
-9.8%
EPS (diluted)
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
$-0.08
$0.86
Q3 25
$0.06
$0.08
Q2 25
$-0.17
$-0.14
Q1 25
$-0.20
$-0.03
Q4 24
$-0.22
$0.96
Q3 24
$-0.22
$0.16
Q2 24
$-0.31
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADPT
ADPT
TBCH
TBCH
Cash + ST InvestmentsLiquidity on hand
$77.6M
$17.0M
Total DebtLower is stronger
$55.7M
Stockholders' EquityBook value
$128.5M
Total Assets
$505.9M
$269.1M
Debt / EquityLower = less leverage
0.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADPT
ADPT
TBCH
TBCH
Q1 26
$77.6M
Q4 25
$70.5M
$17.0M
Q3 25
$55.0M
$12.3M
Q2 25
$43.2M
$11.7M
Q1 25
$50.6M
$11.7M
Q4 24
$47.9M
$13.0M
Q3 24
$38.1M
$13.8M
Q2 24
$59.8M
$12.5M
Total Debt
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
$55.7M
Q3 25
$57.9M
Q2 25
$43.3M
Q1 25
$48.6M
Q4 24
$49.0M
Q3 24
$49.3M
Q2 24
$49.6M
Stockholders' Equity
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
$218.8M
$128.5M
Q3 25
$204.4M
$110.7M
Q2 25
$179.7M
$116.8M
Q1 25
$190.4M
$120.9M
Q4 24
$202.7M
$120.6M
Q3 24
$223.8M
$101.8M
Q2 24
$241.6M
$105.3M
Total Assets
ADPT
ADPT
TBCH
TBCH
Q1 26
$505.9M
Q4 25
$512.7M
$269.1M
Q3 25
$490.6M
$278.2M
Q2 25
$496.6M
$240.2M
Q1 25
$510.9M
$247.0M
Q4 24
$539.4M
$298.9M
Q3 24
$558.5M
$313.2M
Q2 24
$584.9M
$264.4M
Debt / Equity
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
0.43×
Q3 25
0.52×
Q2 25
0.37×
Q1 25
0.40×
Q4 24
0.41×
Q3 24
0.48×
Q2 24
0.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADPT
ADPT
TBCH
TBCH
Operating Cash FlowLast quarter
$13.3M
Free Cash FlowOCF − Capex
$13.1M
FCF MarginFCF / Revenue
13.8%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
0.76×
TTM Free Cash FlowTrailing 4 quarters
$34.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
$2.1M
$13.3M
Q3 25
$-7.1M
$-15.2M
Q2 25
$-12.4M
$-3.1M
Q1 25
$-28.5M
$40.5M
Q4 24
$-12.5M
$14.3M
Q3 24
$-27.1M
$-23.2M
Q2 24
$-17.3M
$-12.6M
Free Cash Flow
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
$1.4M
$13.1M
Q3 25
$-7.5M
$-15.9M
Q2 25
$-13.1M
$-3.5M
Q1 25
$-29.7M
$40.3M
Q4 24
$-12.6M
$12.8M
Q3 24
$-27.4M
$-24.6M
Q2 24
$-19.0M
$-13.9M
FCF Margin
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
2.0%
13.8%
Q3 25
-8.0%
-19.7%
Q2 25
-22.2%
-4.3%
Q1 25
-56.7%
63.0%
Q4 24
-26.5%
8.8%
Q3 24
-59.0%
-26.1%
Q2 24
-44.1%
-18.1%
Capex Intensity
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
0.9%
0.3%
Q3 25
0.4%
0.8%
Q2 25
1.1%
0.4%
Q1 25
2.4%
0.3%
Q4 24
0.2%
1.0%
Q3 24
0.7%
1.5%
Q2 24
4.0%
1.6%
Cash Conversion
ADPT
ADPT
TBCH
TBCH
Q1 26
Q4 25
0.76×
Q3 25
-0.75×
-8.84×
Q2 25
Q1 25
Q4 24
0.71×
Q3 24
-6.79×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADPT
ADPT

Segment breakdown not available.

TBCH
TBCH

Europe And Middle East$71.0M75%
Asia Pacific$13.3M14%
Other$10.8M11%

Related Comparisons